Morehouse School of Medicine (MSM) researchers say they have discovered a novel post-translational mechanism that will have global effect on the gene expression, diff erentiation, cancer andother human diseases.
Shyam Reddy, Ph.D., professor and co-director, Cancer Biology Program, and Georgia Cancer Coalition distinguished cancer scholar, and his group say they have shown for the first time transcription factor CBP-mediated post-translational N-glycosylation of BRCA2 protein (involved in breast, ovarian and prostate cancers) Their work appears in the International Journal of Oncology 35: 387-391, 2009.
The majority of N-linked glycosylation of proteins occur in secretory and membrane proteins. This typical N-glycosylation of a protein takes place upon entry of the protein into the lumen of endoplasmic reticulum (ER), where there is a transfer of carbohydrate moiety to asparagine residue present in the protein.
In bacteria, N-glycosylation can occur independently of the protein traslocation. Here, Reddy and his group find that such protein modifications can also occur even in eukaryotic cells. They show that transcriptional cofactor CBP interacts with BRCA2 protein and mediates its N-glycosylation both in vitro and in vivo.
This is the first report that a transcription cofactor like CBP may be involved in protein translocation-independent N-glycosylation, they say.
Reddy predicts that this CBP-mediated post-translational modification may be a signal for degradation of CBP interacting proteins.
Interestingly, BRCA2 protein is known to be ubiquitinated and degraded by the proteosomal pathway. Reddy is presently testing this hypothesis. Since CBP cofactor interacts with many oncoproteins,tumor suppressors and transcription factors, such a signal may be vital to regulate the expression of these interacting proteins which play an important role in cell growth, differentiation and cell death.